실시간

Endpoints NewsHealth groups say HHS is trying to 'rush reinstatement' of ACIP Endpoints NewsB cell therapy maker Be Bio stops hemophilia trial Clinical OMICsFibroblast Signaling Pathways Linked to Angiogenesis Differences in NSCLC Endpoints NewsFDA raises no major red flags with Moderna's flu shot FierceBiotechEli Lilly’s M&A spree continues with acquisition of non-opioid pain drugmaker 4E FierceBiotechAmenable FDA review bodes well for Moderna's mRNA flu shot ahead of adcomm grilling Clinical OMICsMini Brains Help Identify Treatment for Rare Form Parkinson’s Disease Endpoints NewsFDA greenlights Colorado's drug import proposal CellThe critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM FierceBiotechPE firm Altaris scoops up AI drug development outfit Simulations Plus for $375M BioPharma DiveLilly buys non-opioid pain drugmaker 4E BioPharma DiveExpress Scripts, PCMA sue to block Tennesee law breaking up PBMs and pharmacies

BioWorld 2026년 6월 16일

For clonal hematopoiesis, epigenetics can be in driver’s seat

Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitab...

Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable feature of aging. Certainly, it is near universal in those older than 60. CH is not itself a disease, but 1%-2% of CH cases progress to acute myeloid leukemia, and it raises the risk of some other types of cancer as well. A total of eight genes are responsible for 95% of CH cases, George Vassiliou told the audience in Saturday’s plenary session at the 2026 Annual Congress of the European Hematology Association (EHA 2026).